Home LiteratureArticle Details
PMID: 15078953 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

Journal of virology ·Vol. 78 ·No. 9 ·2004-05-00 ·Pages 4710-9

Bower JF, Yang X, Sodroski J, Ross TM

Abstract

DNA vaccines expressing the envelope (Env) of human immunodeficiency virus type 1 (HIV-1) have been relatively ineffective at generating high-titer, long-lasting immune responses. Oligomeric or trimeric (gp140) forms of Env that more closely mimic the native proteins on the virion are often more effective immunogens than monomeric (gp120) envelopes. In this study, several forms of Env constructed from the HIV-1 isolate YU-2 (HIV-1(YU-2)) were tested for their immunogenic potential: a trimeric form of uncleaved (-) Env stabilized with a synthetic trimer motif isolated from the fibritin (FT) protein of the T4 bacteriophage, sgp140(YU-2)(-/FT), was compared to sgp140(YU-2)(-) without a synthetic trimerization domain, as well as to monomeric gp120(YU-2). DNA plasmids were constructed to express Env alone or fused to various copies of murine C3d (mC3d). BALB/c mice were vaccinated (day 1 and week 4) with DNA expressing a codon-optimized envelope gene insert, alone or fused to mC3d. Mice were subsequently boosted (week 8) with the DNA or recombinant Env protein. All mice had high anti-Env antibody titers regardless of the use of mC3d. Sera from mice vaccinated with DNA expressing non-C3d-fused trimers elicited neutralizing antibodies against homologous HIV-1(YU-2) virus infection in vitro. In contrast, sera from mice inoculated with DNA expressing Env-C3d protein trimers elicited antibody that neutralized both homologous HIV-1(YU-2) and heterologous HIV-1(ADA), albeit at low titers. Therefore, DNA vaccines expressing trimeric envelopes coupled to mC3d, expressed in vivo from codon-optimized sequences, elicit low titers of neutralizing antibodies against primary isolates of HIV-1.

MeSH Terms
AIDS Vaccines/immunology Animals Complement C3d/genetics,immunology,metabolism Gene Products, env/genetics,immunology,metabolism HIV Antibodies/blood HIV Infections/prevention & control HIV-1/immunology Humans Immunization Mice Mice, Inbred BALB C Neutralization Tests Recombinant Fusion Proteins/immunology Vaccines, DNA/immunology env Gene Products, Human Immunodeficiency Virus
Chemicals
AIDS Vaccines Gene Products, env HIV Antibodies Recombinant Fusion Proteins Vaccines, DNA env Gene Products, Human Immunodeficiency Virus gp140 envelope protein, Human immunodeficiency virus 1 Complement C3d
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Bower Joseph F
Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA.
Yang Xinzhen
Sodroski Joseph
Ross Ted M
References (68)
68 references, click to expand
  1. Codon usage limitation in the expression of HIV-1 envelope glycoprotein.
    Curr Biol. 1996 Mar 1;6(3):315-24 PMID: 8805248
  2. CD21 augments antigen presentation in immune individuals.
    Eur J Immunol. 1997 Jan;27(1):122-9 PMID: 9022008
  3. HIV-1 Env glycoproteins from two series of primary isolates: replication phenotype and immunogenicity.
    Virology. 1997 Mar 3;229(1):269-78 PMID: 9123870
  4. Core structure of gp41 from the HIV envelope glycoprotein.
    Cell. 1997 Apr 18;89(2):263-73 PMID: 9108481
  5. Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer.
    J Biol Chem. 2001 Oct 26;276(43):39577-85 PMID: 11514580
  6. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.
    J Virol. 2002 Mar;76(6):2835-47 PMID: 11861851
  7. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin.
    J Virol. 2002 May;76(9):4634-42 PMID: 11932429
  8. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.
    J Virol. 2002 Jun;76(11):5357-68 PMID: 11991964
  9. Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.
    J Virol. 2002 Aug;76(15):7760-76 PMID: 12097589
  10. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
    J Virol. 2002 Sep;76(17):8875-89 PMID: 12163607
  11. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.
    J Virol. 2003 Feb;77(3):2046-55 PMID: 12525639
  12. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins.
    Vaccine. 2003 Feb 14;21(9-10):902-14 PMID: 12547601
  13. Impact of codon usage modification on T cell immunogenicity and longevity of HIV-1 gag-specific DNA vaccines.
    Intervirology. 2002;45(4-6):275-86 PMID: 12566710
  14. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.
    J Virol. 2003 Mar;77(5):3119-30 PMID: 12584337
  15. HIV vaccine development: lessons from the past and promise for the future.
    Curr HIV Res. 2003 Jan;1(1):101-20 PMID: 15043215
  16. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes.
    J Exp Med. 1988 Apr 1;167(4):1428-41 PMID: 3258626
  17. Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes.
    J Immunol. 1988 Jul 15;141(2):457-63 PMID: 2968402
  18. The macrophage in the persistence and pathogenesis of HIV infection.
    AIDS. 1989 Aug;3(8):475-95 PMID: 2508709
  19. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.
    Proc Natl Acad Sci U S A. 1990 Jan;87(2):648-52 PMID: 2300552
  20. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Nature. 1990 Jun 14;345(6276):622-5 PMID: 2190095
  21. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.
    J Virol. 1991 Jan;65(1):31-41 PMID: 1985202
  22. Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.
    Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3097-101 PMID: 2014229
  23. Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus.
    AIDS Res Hum Retroviruses. 1991 Oct;7(10):791-8 PMID: 1742074
  24. Induction of IFN-alpha in peripheral blood mononuclear cells by HIV-infected monocytes. Restricted antiviral activity of the HIV-induced IFN.
    J Immunol. 1992 Jan 15;148(2):422-9 PMID: 1729362
  25. Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein.
    AIDS Res Hum Retroviruses. 1993 Jul;9(7):589-94 PMID: 8369163
  26. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.
    J Virol. 1994 May;68(5):3015-26 PMID: 7512157
  27. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.
    Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11699-703 PMID: 7972127
  28. Co-ligation of mouse complement receptors 1 and 2 with surface IgM rescues splenic B cells and WEHI-231 cells from anti-surface IgM-induced apoptosis.
    Eur J Immunol. 1995 Apr;25(4):1013-7 PMID: 7737272
  29. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity.
    Annu Rev Immunol. 1995;13:127-49 PMID: 7542009
  30. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.
    J Virol. 2000 May;74(10):4746-54 PMID: 10775613
  31. Studies on antibody responses following neonatal immunization with influenza hemagglutinin DNA or protein.
    Virology. 1999 May 10;257(2):406-14 PMID: 10329551
  32. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins.
    Clin Chem Lab Med. 1999 Mar;37(3):199-204 PMID: 10353461
  33. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.
    Vaccine. 1999 Apr 23;17(17):2166-75 PMID: 10367950
  34. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.
    J Virol. 2000 Jun;74(12):5716-25 PMID: 10823881
  35. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
    J Virol. 2000 Jan;74(2):627-43 PMID: 10623724
  36. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.
    J Virol. 2000 Mar;74(6):2628-35 PMID: 10684277
  37. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.
    J Virol. 1997 Jun;71(6):4319-30 PMID: 9151820
  38. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Virology. 1997 Apr 14;230(2):265-74 PMID: 9143282
  39. Atomic structure of the ectodomain from HIV-1 gp41.
    Nature. 1997 May 22;387(6631):426-30 PMID: 9163431
  40. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.
    J Virol. 1997 Jul;71(7):5069-79 PMID: 9188572
  41. Structure of bacteriophage T4 fibritin: a segmented coiled coil and the role of the C-terminal domain.
    Structure. 1997 Jun 15;5(6):789-98 PMID: 9261070
  42. The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2).
    J Immunol. 1997 Oct 15;159(8):3782-91 PMID: 9378965
  43. Atomic structure of a thermostable subdomain of HIV-1 gp41.
    Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12303-8 PMID: 9356444
  44. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage.
    J Virol. 1998 Feb;72(2):1497-503 PMID: 9445053
  45. DNA vaccines for immunodeficiency viruses.
    AIDS. 1997;11 Suppl A:S109-19 PMID: 9451974
  46. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.
    Science. 1998 Jun 19;280(5371):1884-8 PMID: 9632381
  47. Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain.
    J Virol. 1998 Sep;72(9):7620-5 PMID: 9696864
  48. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.
    J Virol. 1998 Nov;72(11):9092-100 PMID: 9765454
  49. The complement system and adaptive immunity.
    Semin Immunol. 1998 Oct;10(5):355-61 PMID: 9799710
  50. DNA vaccines.
    Dev Biol Stand. 1998;95:43-53 PMID: 9855413
  51. DNA vaccines. Mechanisms for generation of immune responses.
    Adv Exp Med Biol. 1998;452:187-91 PMID: 9889973
  52. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage.
    J Virol. 1999 Mar;73(3):2343-9 PMID: 9971817
  53. Cutting edge: recruitment of the CD19/CD21 coreceptor to B cell antigen receptor is required for antigen-mediated expression of Bcl-2 by resting and cycling hen egg lysozyme transgenic B cells.
    J Immunol. 1999 Apr 15;162(8):4377-80 PMID: 10201971
  54. DNA vaccines for viral infections: basic studies and applications.
    Adv Virus Res. 2000;55:1-74 PMID: 11050940
  55. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
    J Virol. 2001 Jan;75(2):645-53 PMID: 11134278
  56. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.
    J Virol. 2001 Feb;75(3):1165-71 PMID: 11152489
  57. Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide.
    Infect Immun. 2001 May;69(5):3031-40 PMID: 11292721
  58. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.
    Nat Immunol. 2000 Aug;1(2):127-31 PMID: 11248804
  59. Stabilization of short collagen-like triple helices by protein engineering.
    J Mol Biol. 2001 May 18;308(5):1081-9 PMID: 11352592
  60. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    J Virol. 2001 Jun;75(12):5526-40 PMID: 11356960
  61. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.
    AIDS Res Hum Retroviruses. 2001 Jun 10;17(9):829-35 PMID: 11429124
  62. C3d enhancement of neutralizing antibodies to measles hemagglutinin.
    Vaccine. 2001 Oct 12;20(1-2):242-8 PMID: 11567770
  63. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.
    J Virol. 2001 Nov;75(22):10991-1001 PMID: 11602739
  64. Candidate AIDS vaccines.
    N Engl J Med. 1995 Nov 16;333(20):1331-9 PMID: 7566026
  65. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity.
    Science. 1996 Jan 19;271(5247):348-50 PMID: 8553069
  66. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA.
    Vaccine. 1995;13(15):1427-30 PMID: 8578820
  67. Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly.
    Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3099-104 PMID: 8610175
  68. Particle-mediated nucleic acid immunization.
    J Biotechnol. 1996 Jan 26;44(1-3):37-42 PMID: 8717384
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2004-05-00
Pages
4710-9
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC387675
Subset
IM
Grants
NIAID NIH HHS · AI31783 · United States
NIAID NIH HHS · AI44325 · United States
NIAID NIH HHS · R01 AI031783 · United States
NIAID NIH HHS · AI44328 · United States
NIAID NIH HHS · AI57630 · United States
NIAID NIH HHS · R21 AI044325-02 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com